 SAN DIEGO, Feb. 22, 2021 GLOBE NEWSWIRE -- Otonomy, Inc. Nasdaq: OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménières disease did not achieve the primary endpoint, which was the count of definitive vertigo days DVD in Month 3 for OTIVIDEX vs. placebo for the intent-to-treat ITT population n 148; p value 0.312 using the Negative Binomial Model. This analysis did achieve statistical significance for the per protocol PP population n 136; p value 0.031. These results were similar using the Generalized Poisson model p value 0.340 for ITT and p value 0.030 for PP. 